Stockscreener 앱 받기
8.86
7.90%
-0.76
시간 외 거래:
8.95
0.09
+1.02%
전일 마감가:
$9.62
열려 있는:
$9.65
하루 거래량:
747.23K
Relative Volume:
2.50
시가총액:
$504.70M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-7.3833
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-5.94%
1개월 성능:
+19.25%
6개월 성능:
+140.76%
1년 성능:
+41.76%
1일 변동 폭
$8.69
$9.68
1주일 범위
$8.69
$9.68
52주 변동 폭
$2.60
$10.31
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
8.86 | 547.99M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Craig Hallum | Buy |
| 2025-12-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5%Should You Sell? - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 5.8%Time to Sell? - MarketBeat
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $14.00 - Defense World
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why retail investors pile into Design Therapeutics Inc. stockJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress By Investing.com - Investing.com South Africa
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7 - MarketScreener
Will Design Therapeutics Inc. stock deliver shareholder valueWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Design Therapeutics (DSGN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Yahoo Finance
How Design Therapeutics Inc. stock performs in weak economyNew Guidance & Safe Entry Point Alerts - Newser
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Will Aries Agro Limited Stock Benefit From Industry Trends in YEARSupport Level Holds & Free Double Digit Growth Tips - earlytimes.in
How sustainable is Design Therapeutics Inc. stock dividend payoutWeekly Trend Summary & Breakout Confirmation Alerts - BỘ NỘI VỤ
Design Therapeutics (NASDAQ:DSGN) Trading Up 9%What's Next? - MarketBeat
Why Design Therapeutics Inc. stock is rated strong buyWeekly Market Report & Consistent Income Trade Recommendations - BỘ NỘI VỤ
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Design Therapeutics (Nasdaq: DSGN) to Participate in Piper Sandler and Evercore 2025 Events - Stock Titan
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - simplywall.st
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighStill a Buy? - MarketBeat
Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
RBC Capital Upgrades Design Therapeutics (DSGN) - Nasdaq
Design Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - Markets Financial Content
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says - MarketScreener
Design Therapeutics stock up as RBC upgrades (DSGN:NASDAQ) - Seeking Alpha
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - Benzinga
Design Therapeutics : DSGN - 24/7 Wall St.
Design Therapeutics stock rating upgraded by RBC Capital on improved outlook - Investing.com Nigeria
RBC Upgrades Design Therapeutics to Outperform From Sector Perform, Boosts Price Target to $13 From $6, Keeps Speculative Risk - MarketScreener
Can Design Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Breakouts & Safe Entry Point Identification - newser.com
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global - openPR.com
Why retail investors favor Design Therapeutics Inc. stockJuly 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Is Design Therapeutics Inc. stock poised for growthTrade Analysis Summary & Safe Swing Trade Setups - newser.com
How to interpret RSI for Design Therapeutics Inc. stock2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Can Design Therapeutics Inc. stock sustain institutional interest - newser.com
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):